NYSE: PENPenumbra Inc Stock
$203.73-0.31 (-0.15%)
Updated Sep 6, 2024
PEN Price
$203.73
Fair Value Price
N/A
Market Cap
$7.91B
52 Week Low
$148.00
52 Week High
$302.00
P/E
536.13x
P/B
6.81x
P/S
6.16x
PEG
3.95x
Dividend Yield
N/A
Revenue
$1.13B
Earnings
$14.23M
Gross Margin
62.5%
Operating Margin
-1.04%
Profit Margin
1.3%
Debt to Equity
0.32
Operating Cash Flow
$128M
Beta
0.98
Next Earnings
Oct 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PEN Overview
Penumbra, Inc. manufactures medical devices in the U.S. and internationally. Offerings include aspiration-based thrombectomy systems and accessory devices under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, and neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names. Penumbra was incorporated in 2004 and is headquartered in Alameda, CA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PEN ($203.73) is trading above its intrinsic value of $20.15, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PEN is poor value based on its earnings relative to its share price (536.13x), compared to the US market average (24.57x)
P/E vs Market Valuation
PEN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more PEN due diligence checks available for Premium users.
Be the first to know about important PEN news, forecast changes, insider trades & much more!
PEN News
Valuation
PEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
536.13x
Industry
41.46x
Market
24.57x
PEN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PEN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
PEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.81x
Industry
4.02x
PEN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PEN price to earnings growth (PEG)
For valuing profitable companies with growth potential
PEN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
PEN's financial health
Profit margin
Revenue
$299.4M
Net Income
-$60.2M
Profit Margin
-20.1%
PEN's Earnings (EBIT) of -$11.79M... subscribe to Premium to read more.
Interest Coverage Financials
PEN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.5B
Liabilities
$373.3M
Debt to equity
0.32
PEN's short-term assets ($943.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PEN's short-term assets ($943.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PEN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$22.6M
Investing
$34.5M
Financing
$8.3M
PEN's operating cash flow ($128.01M)... subscribe to Premium to read more.
Debt Coverage Financials
PEN vs Medical Device Stocks
Penumbra Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.